ArticleAngiogenesis2022

Successful management of lung adenocarcinoma with ALK/EGFR co-alterations and PD-L1 over-expression by bevacizumab combined with chemotherapy.

Hengqiu He et al.PubMed ↗Publisher ↗

No numbers read from the abstract.